SCIENTIFIC INDUSTRIES INC

Form 10QSB May 17, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

(Mark One)

X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For quarterly period ended MARCH 31, 2004

TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT

For the transition period from to

Commission File Number: 0-6658

SCIENTIFIC INDUSTRIES, INC.

(Exact name of small business issuer as specified in its charter)

Delaware 04-2217279

(State of incorporation) (I.R.S. Employer Identification No.)

70 ORVILLE DRIVE, BOHEMIA, NEW YORK 11716

(Address of principal executive offices)

(631)567-4700 (Issuer's telephone number)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [x] No []

State the number of shares outstanding of each of the issuer's classes of common equity, as of April 30, 2004: 975,541 shares outstanding of the Company's Common Stock, par value, \$.05.

Transitional Small Business Disclosure Format (check one): Yes [] No [x]

PART I--FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARY UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET

ASSETS

March 31, 2004

Current Assets:		
Cash and cash equivalents	\$	•
Investment securities Trade accounts receivable, less allowance for		644,700
doubtful accounts of \$7,400		440,900
Inventories		623,000
Prepaid expenses and other current assets	_	50,600
Total current assets		,084,800
Property and equipment at cost, less accumulated depreciation of \$432,200		155,700
Other assets and deferred charges:		
Intangible assets, less accumulated amortization of \$40,300		11,900
Deferred taxes		113,600
Other		66,400
		191,900
		,432,400
	===	
LIABILITIES AND SHAREHOLDERS'	EQU	JITY
Current Liabilities:	<u> </u>	04 500
Accounts payable Accrued expenses	\$	94,500 206,500
neer dear empended		
Total current liabilities		301,000
Deferred compensation		34,700
Shareholders' equity:		
Common stock \$.05 par value; authorized		
7,000,000 shares; 995,343 issued and outstanding	ſ	49,800
Additional paid-in capital Accumulated other comprehensive gain, unrealized		983,400
holding gain on investment securities		4,800
Retained earnings	1,	111,100
		149,100
Less common stock held in treasury, at cost;	۷,	, 113, 100
19,802 shares		52,400
		,096,700
		,432,400
	===	

See notes to unaudited condensed consolidated financial statements

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME

	For the Three Month Periods Ended March 31,				Рe	For the Nine Month Periods Ended March 31,			
		2004		2003		2004	2	003	
Net sales Cost of goods sold				792,600 471,900	\$2 1	,600,500 ,379,900	1,		
Gross profit		•		320,700	1	,220,600	1,		
Operating Expenses: General and administrative Selling Research and development		170,100 69,900 93,800		166,600 63,400				140,000	
Income from operations		68,000		27,600		186,600		22,800	
Interest and other income		5,600		2,600		12,700		7,100	
Income before income taxes		73,600		30,200		199,300		29,900	
Income taxes		25,000		6,400		60,000		6,400	
Net income	\$	48 , 600	\$	23,800	\$	139,300	\$	23,500	
Net income per common share - basic Net income per common		.05						.02	
share - diluted Cash dividends declared per common share		.05	\$		•	.14	\$.02	

See notes to unaudited condensed consolidated financial statements

2

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Nine Month Periods Ended March 31, 2004 March 31, 2003

Operating activities:				
Net income	\$	139,300		\$ 23,500
Adjustments to reconcile net income to net cash provided by				
operating activities:				
(Gain) loss on sale of investments		800	(800)
Loss on disposal of assets		200	,	6 , 400
Depreciation and amortization		52,100		48,500
Change in assets and liabilities:				
Accounts receivable	(31,300)	(108,700)
Inventories	(40,800)		76,000
Prepaid expenses and other				
current assets		14,000		23,400
Other assets		9,000		25,800
Accounts payable		36,400	(
Accrued expenses		80,200	(23,400)
Deferred compensation	(9,100)	(21,200)
Total adjustments		111,500		17,700
Net cash provided by				
operating activities		250,800		41,200
Investing activities:				
Purchase of investment securities,				
available for sale	(171 600)	,	227,000)
Purchase of investment securities,	(1/1,000)	(227,000)
held to maturity		_	(72,600)
Redemptions of investment securities,			(72,000)
available-for-sale		92,600		80,000
Redemptions of investment securities,		32,000		00,000
held to maturity		130,800		110,600
Capital expenditures	(49,400)	(
Proceeds from sale of fixed assets	`	200	`	31,000
Purchase of intangible assets		_	(12,800)
•				
Net cash provided by (used i	in)			
investing activities		2,600	(142,700)
Financing activities:				
Exercise of stock options		12,900		6,600
Cash dividend declared and paid	(48,300)		-
cash dividend declared and pard		40,300)		
Net cash provided by				
(used in) financing				
activities	(35,400)		6,600
Net increase (decrease) in cash and cash				
equivalents		218,000	(94,900)
Cash and cash equivalents, beginning of year		107,600		296,800
Cook and gook agriculants and of namind		325 600		201 000
Cash and cash equivalents, end of period	\$ ===	325 , 600	\$ ==	201,900 ======
Supplemental disclosures:				
Cash paid during the period for:				
Income Taxes	\$	200	\$	29 , 800

See notes to unaudited condensed consolidated financial statements

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

General:

The accompanying unaudited interim consolidated financial statements are prepared pursuant to the Securities and Exchange Commission's rules and regulations for reporting on Form 10-QSB. Accordingly, certain information and footnotes required by accounting principles generally accepted in the United States for complete financial statements are not included herein. The Company believes all adjustments necessary for a fair presentation of these interim statements have been included and are of a normal and recurring nature. These interim statements should be read in conjunction with the Company's financial statements and notes thereto, included in its Annual Report on Form 10-KSB for the fiscal year ended June 30, 2003. The results for the three and nine months ended March 31, 2004, are not necessarily an indication of the results of the full fiscal year.

1. Significant accounting policies:

Principles of consolidation:

The accompanying condensed consolidated financial statements include the accounts of the Company and Scientific Packaging Industries, Inc., a New York corporation and an inactive wholly owned subsidiary of the Company. All intercompany items and transactions have been eliminated in consolidation.

2. Line of Business and Concentrations:

The Company is engaged in the manufacturing and marketing of equipment for research in university, hospital and industrial laboratories. The Company believes that it has only one reportable segment. Sales of the Company's principal product, the Vortex-Genie(R) 2 mixer, accounted for approximately 76% and 77% of net sales for the three month periods ended March 31, 2004 and 2003, respectively and 77% and 82% of net sales for the nine month periods ended March 31, 2004 and 2003, respectively.

The Company's export sales (principally Europe and Asia) were approximately \$414,000 and \$341,700 for the three month periods ended March 31, 2004 and 2003, respectively, and \$1,165,800 and \$1,224,000 for the nine month periods ended March 31, 2004 and 2003, respectively.

Three of the Company's customers accounted in the aggregate for 49% and 53% of net sales for the three month periods ended March 31, 2004 and 2003, respectively, and 54% and 51% of total net sales for the nine month periods ended March 31, 2004 and 2003, respectively.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(continued)

3. Inventories:

Inventories for interim financial statement purposes are based on perpetual inventory records at the end of the applicable periods. Components of inventory are as follows:

	March	31, 2004
Raw Materials Work in process Finished Goods	\$	543,400 34,800 44,800
	 \$ =====	623 , 000

4. Net income per common share:

Basic net income per common share is computed by dividing net income by the weighted-average number of shares outstanding. Diluted net income per common share includes the dilutive effect of stock options and a warrant.

Net income per common share was computed as follows:

	For the Three Month Periods Ended March 31,					Periods Ended			
				2003		2004		2003	
Net income	\$ 4	8,600	\$	23,800	\$		\$	23,500	
Weighted average common shares outstanding					Ğ	961,817		954 , 180	
Effect of dilutive securities	7	2 , 676		32,776		48,971		41,865	
Weighted average dilutive common shares outstanding		7 , 074		990,250)10 , 788	==	996 , 045	
Net income per common share - basic	\$.05	\$.02	\$.14	\$.02	
Net income per common share - diluted	\$.05	\$.02	\$.14	\$.02	

5. Comprehensive Income:

There was no significant difference between net income and

comprehensive income for the three and nine month periods ended March 31, 2004 and 2003.

5

6. Stock-Based Compensation Plans:

The Company maintains an Incentive Stock Option Plan which it accounts for under the recognition and measurement principles of APB Opinion No. 25, "Accounting for Stock Issued to Employees," and related Interpretations. No stock-based compensation costs are reflected in net income, as all options granted under those plans had an exercise price equal to the market value of the underlying common stock on the date of grant. The following table illustrates the effect on net income and earnings per share if the Company had applied the fair value recognition provisions of FASB Statement No. 123, "Accounting for Stock-Based Compensation," to stock-based employee compensation:

	For the The Periods Endarch 31,		For the Nine Month Periods Ended March 31,			
	2004	2003	2004	2003		
Net income:						
As reported	\$ 48,600	\$23,800	\$139,300	\$23,500		
Pro Forma	48,300	23,500	135,700	23,000		
Net income per common an common equivalent share						
Basic - as reported	\$.05	\$.02	\$.14	\$.02		
Basic - pro forma	\$.05	\$.02	\$.14	\$.02		
Diluted - as reported	\$.05	\$.02	\$.14	\$.02		
Diluted - pro forma	\$.05	\$.02	\$.13	\$.02		

6

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARY

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS

Certain statements contained in this report are not based on historical facts, but are forward-looking statements that are based upon various assumptions about future conditions. Actual events in the future could differ materially from those described in the forward-looking information. Numerous unknown factors and future events could cause such differences, including but not

limited to, product demand, market acceptance, success of marketing strategy, impact of competition, the ability to reach final agreements, adverse economic conditions, and other factors affecting the Company's business that are beyond the Company's control. Consequently, no forward-looking statement can be quaranteed.

We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

Liquidity and Capital Resources

Net cash provided by operating activities was \$250,800 for the nine month period of the current fiscal year as compared to \$41,200 in the comparative period for 2003. The principal factors accounting for the difference were (i) higher net income, (ii) lower increase in accounts receivable by \$77,400 because of an unusually large sale to a foreign customer during the three months ended March 31, 2003, and (iii) a \$103,600 increase in accrued expenses mainly due to customer allowances and income tax accruals. Cash provided by investing activities was \$2,600 for the current period as compared to \$142,700 (used in) the nine months ended March 31, 2003 reflecting lesser purchases of investment securities and greater amount of redemptions during the current year and a sale in the prior year period of a previously leased auto related to the termination of the Company's former chief executive officer. The principal reason that cash (used in) financing activities was \$35,400 compared to cash provided of \$6,600 in the prior year period was the \$48,300 cash dividend declared and paid in March 2004. As a result of the foregoing, cash and cash equivalents increased by \$218,000 to \$325,600 as of March 31, 2004 from a balance of \$107,600 as of June 30, 2003.

The Company's working capital as of March 31, 2004 increased \$108,800 to \$1,783,800 compared to \$1,675,000 at June 30, 2003. The increase was generated from profitable operations, partially offset by the cash dividend. The Company has available for its working capital needs, a secured bank line of credit of \$200,000 with North Fork Bank which expires on November 1, 2004 with interest at prime, all of which was available as of March 31, 2004. Management believes that the Company will be able to meet its cash flow needs during the next 12 months from its available financial resources which include its cash and investment securities.

7

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARY

Results of Operations

Financial Overview

Commencing in January 2003, the Company substantially increased its marketing and product development efforts and expenditures under its revised strategy for sales growth with (i) the employment of a Director of Sales and Marketing, (ii) an expanded promotion and advertising program, and (iii) increased commitment

of funds to research and development activity.

The Company also intensified its efforts to increase the Company's profitability by continuing to seek economies through a search for alternative, lower cost quality sources for its material components (mostly from overseas), and evaluating its labor requirements on an ongoing basis for achievement of overall cost reductions.

Primarily as a result of these factors, the Company reflected increases for the three and nine month periods ended March 31, 2004 over the three and nine month periods ended March 31, 2003 as follows:

- * Increases in net sales of 8.1% and 5%, respectively.
- * Increases in gross profit margin percentages of 6.4% and 6.2%, respectively.
- * Increases in selling expenses of 10.3% and 77.4%, respectively.
- * Increases in research and development expenses of 48.7% and 39.1%, respectively.

These increases in sales and gross profit margins were the principal reason for the improvement in net income to \$48,600 and \$139,300 for the three and nine months ended March 31, 2004 from \$23,800 and \$23,500, respectively for the year earlier comparable periods.

The Three Months Ended March 31, 2004 Compared with the Three Months Ended March 31, 2003.

Net sales for the three months ended March 31, 2004 increased by \$64,300 (8.1%) to \$856,900 from \$792,600 for the three months ended March 31, 2003, primarily the result of a \$40,000 increase to \$648,000 in sales of our Vortex-Genie 2(R) mixer, mainly to overseas customers, a \$31,000 increase to \$151,000 from \$123,000 in sales of our new products, especially the Vortex Genie(R) 1 and Vortex-Genie 2T, and higher product accessory sales for all of our products. The gross profit was \$401,800 for the three months ended March 31, 2004, a gross profit margin of 46.9% as compared with \$320,700, a gross profit margin of 40.5% for the three months ended March 31, 2003, primarily due to increased overseas purchases of material components for the Vortex-Genie(R) 2 mixer at lower cost, and lower labor and labor related costs.

There was little change in general and administrative expenses for the three months ended March 31, 2004 - a slight increase of \$3,500 to \$170,100 from \$166,600 for the three months ended March 31, 2003.

8

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARY

Selling expenses for the three months ended March 31, 2004 increased 6,500 (10.3%) to 69,900 as compared to 63,400 for the three months ended March 31, 2003, mainly due to advertising expenses which the company began incurring at the end of fiscal

year 2003.

Research and development expenses increased by \$30,700 (48.7%) to \$93,800 for the three months ended March 31, 2004 from \$63,100 for the comparable prior year period as a result of increased new product development.

The Company's income before income taxes increased \$43,400 (144%) to \$73,600 for the three months ended March 31, 2004 compared to \$30,200 for the three months ended March 31, 2003.

The increase in income tax expense for the three months ended March 31, 2004 to \$25,000 from \$6,400 was a result of the higher income for the current period.

As a result of the foregoing, net income was \$48,600 as compared to \$23,800 for the comparable period last year.

The Nine Months Ended March 31, 2004 Compared with the Nine Months Ended March 31, 2003.

Net sales increased \$123,900 (5.0%) to \$2,600,500 for the nine months ended March 31, 2004 compared to \$2,476,600 for the nine months ended March 31, 2003, primarily due to a \$170,000 increase to \$464,000 from \$294,000 in sales of our new products, especially the Disruptor Genie (TM), Vortex Genie 1 and Vortex Genie 2T and product accessories for all of our products, offset slightly by a \$24,000 decline to \$2,011,000 in the sales of our Vortex-Genie 2 mixer and certain customer allowances.

The gross profit margin of 46.9% for the nine months ended March 31, 2004, was higher than the gross profit margin of 40.7% for the nine months ended March 31, 2003 primarily due to higher margins on average of our new products, increased overseas purchases of material components for the Vortex-Genie 2 mixer at lower cost, and lower labor and labor related costs.

General and administrative expenses for the nine months ended March 31, 2004 were \$497,100, a decrease of \$140,300 (22.0%) from \$637,400 for the nine months ended March 31,2003 which period suffered \$72,300 of proxy costs in connection with the proxy contest initiated by the former Chief Executive Officer, and costs incurred in connection with termination of his employment in August 2002.

Selling expenses for the nine months ended March 31, 2004 increased \$108,400 (77.4%) to \$248,400, from \$140,000 for the nine months ended March 31, 2003, the result of the Company's expansion of its sales and marketing functions, including the hiring of a new director of sales and marketing in January 2003, incurrence of advertising expenses and other marketing activities.

9

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARY

Research and development expenses increased by \$81,100 (39.1%) to \$288,500 for the nine months ended March 31, 2004 from \$207,400

for the comparable prior year period as a result of increased new product development.

The Company's income before income taxes increased to \$199,300 for the nine months ended March 31, 2004 compared to \$29,900 for the nine months ended March 31, 2003.

As a result of the higher income for the period, income tax expense was \$60,000, compared to \$6,400 in the prior year comparable period.

As a result of the foregoing, net income increased to \$139,300 from \$23,500 for the nine month year earlier comparable period.

10

PART II OTHER INFORMATION

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

- (a) Exhibit Number: Description
 - 31.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
 - 32.1 Certification of Chief Executive
 Officer and Chief Financial Officer
 pursuant to Section 906 of the
 Sarbanes-Oxley Act of 2002.
- (b) Reports on Form 8-K:

Registrant filed reports on Form 8-K on February 26, 2004 and March 3, 2004 reporting under Item 5, Other Events and Regulation FD Disclosure.

11

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARY

SIGNATURE

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the

undersigned, thereunto duly authorized.

Scientific Industries, Inc. Registrant

/s/Helena R. Santos

Helena R. Santos President, Chief Executive Officer, Treasurer, and Chief Financial Officer

Date: May 17, 2004

14